Two antihypertensive medications manufactured in India have come under regulatory scrutiny in the United States after the U.S. Food and Drug Administration announced nationwide recalls linked to dissolution-related quality concerns. The latest recall involves 11,460 bottles of chlorthalidone 25 mg tablets manufactured by Inventia Healthcare Limited and distributed in the U.S. by Rising Pharma Holdings.
According to the FDA, the affected lots failed dissolution specifications, raising concerns that the tablets may not release the active ingredient as intended after administration. The recalled products carry an expiration date of April 2027. While the FDA has not publicly detailed specific health risks associated with the recalled chlorthalidone tablets, dissolution failures are closely monitored because they can potentially affect drug bioavailability and therapeutic performance. In the…
